ASML Q1 bookings miss forecast, but China sales hold up
Related Articles
-
J&J first-quarter revenue misses as Stelara sales disappoint
Stelara sales were flat at $2.45 billion in the first quarter and came in below expectations of $2.6 billion, according to LSEG data. J&J has struck deals to delay U.S. launches of close-copy versions of Stelara until 2025, a key patent for which expired last year. Analysts have said the delayed competition will make the drug a larger contributor for J&J's 2024 and 2025 revenue than previously anticipated.
-
Johnson & Johnson's bet on heart devices boosted sales — but it still missed analysts' expectations
Johnson & Johnson’s recent investments in medical devices helped boost sales, but the company’s total revenue in the first quarter of the year failed to beat Wall Street expectations. Its stock fell 2%to about $144 on Tuesday, following the healthcare giant’s recent quarterly earnings report. The company’s medical device segment experienced the biggest growth in the company during the three months ending March 31, up 4.5% year-over-year to $7.8 billion. Johnson & Johnson said the growth was...
-
Critical chip firm ASML posts profit beat but sales miss expectations with 22% drop
ASML on Monday said first quarter profit beat expectations while sales missed forecasts, with the compant sticking to its full-year outlook.